The subsequent OptiTROP-Breast02 phase III trial demonstrated efficacy in previously treated HR+/HER2− metastatic breast cancer, with sac-TMT achieving a median PFS of 8.3 months versus 4.1 months with chemotherapy (HR 0.35; 95% CI, 0.26–0.48; p < 0.0001), along with a favorable trend in overall survival. 43 Biomarkers of response and resistance Identification of biomarkers to guide ADC selection has become increasingly important considering increasing number of agents available.
← all excerpts
Antibody-drug conjugates in breast cancer: Progress and future directions.
1
—
—